Исследование холиномиметических свойств 2-метокси-5-трифторметил-бензальдегида как модулятора сократительной активности гладких мышц слепой кишки крысы
Т. Федирко

, В. Бджола

, С. Старосыла

, И. Войтешенко

, В. Хитченко, К. Писня, К. Жыш-кевич, А. Мусіенко

, О. Ныпорко

, О. Цымбалюк

Резюме: Цель: Оценить фармакологические и кинетические эффекты 2-метокси-5-трифторметилбензальдегида (МТМБА), предсказанные in silico для активации мускариновых ацетилхолиновых рецепторов (мАХР), на сократительную активность гладких мышц слепой кишки крысы. Материал и методы: Эксперименты проводили на препаратах кольцевого слоя гладких мышц слепой кишки крыс линии Wistar с использованием тензометрической регистрации в изометрическом и изотоническом режимах. Механокинетический анализ проводили методом Костерина-Бурдиги для определения нормализованных максимальных скоростей сокращения (Vnc) и расслабления (Vnr). Эффекты МТМБА (10-9-10-6 М) оценивали на индуцированные ацетилхолином сокращения, включая селективное блокирование антагонистами М2 (AF-DX 116) и М3 (4-DAMP). Результаты: MTMBA (10 ⁻⁹ -10 ⁻⁶ M) значительно усиливал тонические компоненты сокращений, вызванных ацетилхолином, указывая на активацию M2 мАХР. При 10 ⁻⁹ -10 ⁻⁸ M MTMBA также увеличивал фазовые компоненты, вероятно, через возбуждение M3 мАХР. При всех концентрациях MTMBA Vnc и Vnr изменялись. Активирующий эффект при 10 ⁻⁸ М был устранен AF DX 116 (антагонист М2), но сохранялся с 4 DAMP (антагонист М3), подтверждая селективность М2. Выводы: MTMBA усиливал индуцированные ацетилхолином сокращения гладких мышц слепой кишки крыс, демонстрируя холиномиметические свойства. При 10 ⁻⁸ M он действовал как селективный агонист M2 мАХР, в то время как при более высоких концентрациях (10 ⁻⁷ -10 ⁻⁶ M) дополнительные клеточные мишени могут способствовать модуляции возбудимости гладких мышц кишечника.
Ключови думи: ацетилхолин; агонист; сокращение; Мускариновые ацетилхолиновые рецепторы; гладкие мышцы
| Литература: (click to open/close) | [1] Ishii, M., Kurachi, Y., 2006. Muscarinic acetylcholine receptors. Current Pharmaceutical Design 12, 3573–3581. [2] Seeger, T., Fedorova, I., Zheng, F., Miyakawa, T., Koustova, E., Gomeza, J., Basile, A. S., Alzheimer, C., Wess, J., 2004. M2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity. The Journal of Neuroscience 24, 10117–10127. [3] Uggenti, C., De Stefano, M. E., Costantino, M., Loreti, S., Pisano, A., Avallone, B., Talora, C., Magnaghi, V., Tata, A. M., 2014. M2 muscarinic receptor activation regulates Schwann cell differentiation and myelin organization. Developmental Neurobiology 74, 676–691. [4] Cai, Y. Q., Chen, S. R., Han, H. D., Sood, A. K., Lopez-Berestein, G., Pan, H. L., 2009. Role of M2, M3, and M4 muscarinic receptor subtypes in the spinal cholinergic control of nociception revealed using siRNA in rats. Journal of Neurochemistry 111, 1000–1010. [5] Bernardini, N., Roza, C., Sauer, S. K., Gomeza, J., Wess, J., Reeh, P. W., 2002. Muscarinic M2 receptors on peripheral nerve endings: a molecular target of antinociception. The Journal of Neuroscience 22, RC229. [6] Chen, S. R., Wess, J., Pan, H. L., 2005. Functional activity of the M2 and M4 receptor subtypes in the spinal cord studied with muscarinic acetylcholine receptor knockout mice. The Journal of Pharmacology and Experimental Therapeutics 313, 765–770. [7] Lucianò, A. M., Perciballi, E., Fiore, M., Del Bufalo, D., Tata, A. M., 2020. The Combination of the M2 Muscarinic Receptor Agonist and Chemotherapy Affects Drug Resistance in Neuroblastoma Cells. International Journal of Molecular Sciences 21, 8433. [8] Español, A. J., Salem, A., Di Bari, M., Cristofaro, I., Sanchez, Y., Tata, A. M., Sales, M. E., 2020. The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2 receptor subtype. PLOS ONE 15, e0226450. [9] Pacini, L., De Falco, E., Di Bari, M., Coccia, A., Siciliano, C., Ponti, D., Pastore, A. L., Petrozza, V., Carbone, A., Tata, A. M., Calogero, A., 2014. M2 muscarinic receptors inhibit cell proliferation and migration in urothelial bladder cancer cells. Cancer Biology & Therapy 15, 1489–1498. [10] Liao, F., Zheng, Y., Cai, J., Fan, J., Wang, J., Yang, J., Cui, Q., Xu, G., Tang, C., Geng, B., 2015. Catestatin attenuates endoplasmic reticulum induced cell apoptosis by activation type 2 muscarinic acetylcholine receptor in cardiac ischemia/reperfusion. Scientific Reports 5, 16590. [11] Dolejší, E., Janoušková, A., Jakubík, J., 2024. Muscarinic Receptors in Cardioprotection and Vascular Tone Regulation. Physiological Research 73 (Suppl 1), S389–S400. [12] Alom, F., Miyakawa, M., Matsuyama, H., Nagano, H., Tanahashi, Y., Unno, T., 2018. Possible antagonistic effects of the TRPC4 channel blocker ML204 on M2 and M3 muscarinic receptors in mouse ileal and detrusor smooth muscles and atrial myocardium. The Journal of Veterinary Medical Science 80, 1407–1415. [13] Alom, F., Matsuyama, H., Nagano, H., Fujikawa, S., Tanahashi, Y., Unno, T., 2019. Involvement of transient receptor potential melastatin 4 channels in the resting membrane potential setting and cholinergic contractile responses in mouse detrusor and ileal smooth muscles. The Journal of Veterinary Medical Science 81, 217–228. [14] Griffin, C. S., Bradley, E., Dudem, S., Hollywood, M. A., McHale, N. G., Thornbury, K. D., Sergeant, G. P., 2016. Muscarinic Receptor Induced Contractions of the Detrusor are Mediated by Activation of TRPC4 Channels. The Journal of Urology 196, 1796–1808. [15] Sá-Caputo, D., Taiar, R., Martins-Anjos, E., Seixas, A., Sartório, A., Sanudo, B., Sonza, A., Amaral, V., Lacerda, A., Gomes-Neto, M., Moura-Filho, O., Oliveira, L., Bachur, J., Bernardo-Filho, M., 2023. Does the mechano-biomodulation vibration lead to biological responses on human beings. Series on Biomechanics 37, 3–17. [16] Goletiani, C., Nebieridze, N., Mantskava, M., Zhvania, M., Songulashvili, D., 2021. Therapeutic effect of discriminated electric stimuli on the bursts in dissociated cortical culture neural networks. Series on Biomechanics 35, 32–41. [17] Zholos, A. V., Dryn, D. O., Melnyk, M. I., 2023. General anaesthesia-related complications of gut motility with a focus on cholinergic mechanisms, TRP channels and visceral pain. Frontiers in Physiology 14, 1174655. [18] Guerriero, C., Manfredelli, M., Matera, C., Iuzzolino, A., Conti, L., Dallanoce, C., De Amici, M., Trisciuoglio, D., Tata, A. M., 2023. M2 Muscarinic Receptor Stimulation Induces Autophagy in Human Glioblastoma Cancer Stem Cells via mTOR Complex-1 Inhibition. Cancers 16, 25. [19] Intachai, K., C Chattipakorn, S., Chattipakorn, N., Shinlapawittayatorn, K., 2018. Revisiting the Cardioprotective Effects of Acetylcholine Receptor Activation against Myocardial Ischemia/Reperfusion Injury. International Journal of Molecular Sciences 19, 2466. [20] Vukova, T., Apostolova, S., Georgieva, I., Tzoneva, R., Antonova, N., 2024. Effect of mechanical stress and blood flow on the adhesion of white blood cells to the endothelium in terms of inflammatory processes. Series on Biomechanics 38, 65–73. [21] Xu, J., Wang, Q., Hübner, H., Hu, Y., Niu, X., Wang, H., Maeda, S., Inoue, A., Tao, Y., Gmeiner, P., Du, Y., Jin, C., Kobilka, B. K., 2023. Structural and dynamic insights into supra-physiological activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature Communications 14, 376. [22] Kaoullas, M. G., Thal, D. M., Christopoulos, A., Valant, C., 2024. Ligand bias at the muscarinic acetylcholine receptor family: Opportunities and challenges. Neuropharmacology 258, 110092. [23] Sapundzhi, F., Georgiev, S., Lazarova, M., Popstoilov, M., 2025. Application of artificial intelligence and machine learning to study the structurebiological activity relationship. Series on Biomechanics 39, 74–84. [24] Kruse, A. C., Kobilka, B. K., Gautam, D., Sexton, P. M., Christopoulos, A., Wess, J., 2014. Muscarinic acetylcholine receptors: novel opportunities for drug development. Nature Reviews Drug Discovery 13, 549–560. [25] Myslivecek, J., 2022. Multitargeting nature of muscarinic orthosteric agonists and antagonists. Frontiers in Physiology 13, 974160. [26] Santiago, L. J., Abrol, R., 2019. Understanding G Protein Selectivity of Muscarinic Acetylcholine Receptors Using Computational Methods. International Journal of Molecular Sciences 20, 5290. [27] Nyporko, A., Tsymbalyuk, O., Voiteshenko, I., Starosyla, S., Protopopov, M., Bdzhola, V., 2023. Computer-aided design of muscarinic acetylcholine receptor M3 inhibitors: Promising compounds among trifluoromethyl containing hexahydropyrimidinones/thiones. Molecular Informatics 42, 2300006. [28] Nyporko, A., Tsymbalyuk, O., Voiteshenko, I., Starosyla, S., Protopopov, M., Bdzhola, V., 2023. New promising agents against COPD and asthma among the amides of 1-oxo-3-phenyl-isochroman-6-carboxylic acid. Biophysical Bulletin 50, 36–47. [29] Tsymbalyuk, O., Voiteshenko, I., Starosyla, S., Bdzhola, V., Prykhodko, A., Fedirko, T., Savchenko, O., Bakhina, A., Nyporko, O., 2023. 8-[(4-benzylpiperazin-1-yl)methyl]-3-(2-chlorophenyl)-7-hydroxy-chromen-4-one is an activator of contractile activity of intestinal smooth muscles with reversible M2 cholinomimetic properties. Studia Biologica 17, 15–36. [30] Burdyga, Th. V., Kosterin, S. A., 1991. Kinetic analysis of smooth muscle relaxation. General Physiology and Biophysics 10, 589–598. [31] Tsymbalyuk, O., Veklich, T., Rodik, R., Maliuk, O., Karakhim, S., Kalchenko, V., Kosterin, S., 2024. Modulation of myometrium contractive activity and intracellular Ca2+ homeostasis by calix4arene С-1130 selective inhibitor of the sodium pump. Series on Biomechanics 38, 71–89. [32] Tanahashi, Y., Komori, S., Matsuyama, H., Kitazawa, T., Unno, T., 2021. Functions of Muscarinic Receptor Subtypes in Gastrointestinal Smooth Muscle: A Review of Studies with Receptor-Knockout Mice. International Journal of Molecular Sciences 22, 926. [33] Kang, H., Kim, J., Park, C. H., Jeong, B., So, I., 2024. Direct modulation of TRPC ion channels by Gα proteins. Frontiers in Physiology 15, 1362987. [34] Sakamoto, T., Unno, T., Kitazawa, T., Taneike, T., Yamada, M., Wess, J., Nishimura, M., Komori, S., 2007. Three distinct muscarinic signalling pathways for cationic channel activation in mouse gut smooth muscle cells. The Journal of Physiology 582, 41–61. [35] Cohen-Armon, M., 2023. Are Voltage Sensors Really Embedded in Muscarinic Receptors?. International Journal of Molecular Sciences 24, 7538. [36] Tauber, M., Ben-Chaim, Y., 2024. Voltage Sensors Embedded in G Protein-Coupled Receptors. International Journal of Molecular Sciences 25, 5295.
|
|
| Дата на публикуване: 2026-07-17
(Price of one pdf file: 25.00 EUR)